The Food and Drug Administration approves daraxonrasib, a new oral pill for advanced pancreatic cancer.

This approach was previously considered difficult for drugmakers to achieve for decades. In a study of 500 patients whose metastatic cancer had stopped responding to prior treatment, patients taking the drug lived for a median of 13.2 months compared to 6.7 months for those receiving chemotherapy. The drug is sold by Revolution Medicines under the brand name Rasonque. A one-month supply costs approximately $39,800. Pancreatic cancer is often difficult to detect early because it lacks many early symptoms and often spreads to quickly to other organs. The drug is not a cure, but it is a significant improvement over previous therapies. Researchers believe the drug's technology could eventually treat other cancers, such as lung cancer, as it uses a molecular glue to bind with multiple KRAS subtypes.